124 related articles for article (PubMed ID: 25648089)
1. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
3. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
4. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Tulsyan S; Chaturvedi P; Singh AK; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
Gene; 2014 Jun; 543(1):69-75. PubMed ID: 24704000
[TBL] [Abstract][Full Text] [Related]
5. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Jabir RS; Ho GF; Annuar MABA; Stanslas J
Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Sone K; Oguri T; Uemura T; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
BMC Cancer; 2019 Mar; 19(1):246. PubMed ID: 30890141
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
8. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Yan M; Fan X; Si H; Wang X; Wang Z; Wang Z; Lv X; Yin H; Jia Y; Jiang L; Xia Y; Liu Y
Cancer Chemother Pharmacol; 2022 Feb; 89(2):173-181. PubMed ID: 34988655
[TBL] [Abstract][Full Text] [Related]
9. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
[TBL] [Abstract][Full Text] [Related]
10. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
Ikeda M; Tsuji D; Yamamoto K; Kim YI; Daimon T; Iwabe Y; Hatori M; Makuta R; Hayashi H; Inoue K; Nakamichi H; Shiokawa M; Itoh K
Drug Metab Pharmacokinet; 2015 Apr; 30(2):149-53. PubMed ID: 25989890
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Sissung TM; Baum CE; Deeken J; Price DK; Aragon-Ching J; Steinberg SM; Dahut W; Sparreboom A; Figg WD
Clin Cancer Res; 2008 Jul; 14(14):4543-9. PubMed ID: 18628469
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.
Tounsi N; Trabelsi I; Kerkeni E; Grissa MH; Fredj N; Sekma A; Mzali M; Hellara I; Monastiri K; Douki W; Nouira S
Pharmacology; 2017; 99(5-6):250-258. PubMed ID: 28208135
[TBL] [Abstract][Full Text] [Related]
15. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.
Sensorn I; Sirachainan E; Chamnanphon M; Pasomsub E; Trachu N; Supavilai P; Sukasem C; Pinthong D
Pharmgenomics Pers Med; 2013; 6():93-8. PubMed ID: 24019753
[TBL] [Abstract][Full Text] [Related]
16. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Huang HN; Yu QZ; Sheng LJ
Respiration; 2009; 78(1):49-55. PubMed ID: 18812689
[TBL] [Abstract][Full Text] [Related]
17. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
Seo T; Ishitsu T; Ueda N; Nakada N; Yurube K; Ueda K; Nakagawa K
Pharmacogenomics; 2006 Jun; 7(4):551-61. PubMed ID: 16753003
[TBL] [Abstract][Full Text] [Related]
19. Influence of ABCB1 genetic variants in breast cancer treatment outcomes.
Chaturvedi P; Tulsyan S; Agarwal G; Lal P; Agarwal S; Mittal RD; Mittal B
Cancer Epidemiol; 2013 Oct; 37(5):754-61. PubMed ID: 23707158
[TBL] [Abstract][Full Text] [Related]
20. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Pucci L; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19589. PubMed ID: 25394094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
